Endoluten

1. Overview

Endoluten (Cytomax A-8) is a natural peptide bioregulator complex extracted from the pineal gland of young calves (under 12 months of age), developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology [1][9]. It contains low-molecular-weight peptides with molecular weights up to 5,000 Da, and occupies a central position in Khavinson's anti-aging program as the oral supplement form of the pineal peptide preparation.

Endoluten is the Cytomax (oral supplement) counterpart of epithalamin, the injectable pineal gland extract that was the subject of Khavinson's most significant longevity research, including a 15-year placebo-controlled follow-up study demonstrating a 28% mortality reduction in elderly cardiovascular patients [3]. The relationship between Endoluten, epithalamin, and the synthetic peptide Epithalon (AEDG) represents three levels of complexity from the same biological source:

• Epithalamin: The original injectable polypeptide extract from bovine pineal gland, used in clinical studies from the 1980s onward
• Endoluten: The oral capsule formulation of pineal peptides, developed for long-term supplementation
• Epithalon (AEDG): The single defined synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from amino acid analysis of epithalamin

Additionally, the tripeptide Pinealon (EDR, Glu-Asp-Arg) was isolated from Cortexin (brain cortex extract) but is functionally associated with pineal activity and is sometimes marketed alongside Endoluten [5].

Khavinson has identified Endoluten as one of the two most critical bioregulators for lifespan extension, alongside Vladonix (thymic peptides). Together, these two preparations demonstrated the ability to extend average lifespan by 30-40% in animal models [1][2].

Type

Polypeptide complex (pineal gland extract), not a single peptide

Source

Bovine pineal gland from calves aged up to 12 months

Molecular Weight Range

Up to 5,000 Da (low-molecular-weight peptide fraction)

Key Synthetic Analogs

Epithalon (AEDG tetrapeptide); Pinealon (EDR tripeptide)

Cytomax Designation

A-8 (pineal gland bioregulator)

Mechanism

Melatonin synthesis restoration; neuroendocrine regulation; antioxidant; circadian rhythm normalization

Route

Oral (capsules); sublingual (Lingual Endoluten)

Developer

Prof. Vladimir Khavinson, St. Petersburg Institute of Bioregulation and Gerontology

Regulatory Status

Available as dietary supplement in Russia; not approved by FDA, EMA, or any Western regulatory agency

2. Mechanism of Action

Endoluten's mechanisms of action are understood primarily through studies of its constituent peptides (Epithalon/AEDG and Pinealon/EDR) and the parent preparation epithalamin.

Melatonin Synthesis Restoration

The primary mechanism of pineal peptide bioregulators is the restoration of age-related decline in melatonin production. In cultured rat pinealocytes, Epithalon (the defined synthetic component of the pineal extract) upregulated the expression of arylalkylamine N-acetyltransferase (AANAT), the rate-limiting enzyme in melatonin biosynthesis [7]. It also increased phosphorylation of CREB (pCREB), the transcription factor that drives AANAT expression [7].

In aged rhesus macaques, pineal peptide administration stimulated evening melatonin production and normalized the circadian amplitude of melatonin secretion, which diminishes with aging [4][10][11]. In a human study of 75 elderly women, sublingual pineal peptide administration produced a 1.6-fold increase in urinary 6-sulfatoxymelatonin (the primary melatonin metabolite) [8].

Circadian Rhythm Normalization

Through its effects on melatonin and clock gene expression, Endoluten normalizes age-related circadian disruption. The AEDG peptide modulates expression of circadian genes, reducing overexpression of Clock and Csnk1e genes while increasing hypoexpression of the Cry2 gene in peripheral blood lymphocytes [8]. Circadian rhythm dysregulation is increasingly recognized as a driver of age-related disease, including metabolic disorders, cardiovascular disease, and neurodegeneration.

Telomerase Activation

The AEDG peptide within the pineal extract has been demonstrated to activate telomerase through upregulation of hTERT (human telomerase reverse transcriptase), the catalytic subunit of the telomerase enzyme [6]. In human fetal fibroblasts, this resulted in telomere elongation and extension of replicative lifespan beyond the Hayflick limit [6][12]. A 2025 independent study confirmed dose-dependent telomere extension in normal cells through hTERT upregulation [16].

Neuroendocrine Regulation

Endoluten peptides regulate metabolism in neuroendocrine cells across various tissues, not just the pineal gland. The preparation increases neuroendocrine system resilience and has favorable effects on organism adaptation processes in extreme conditions [1]. In aged primates, pineal peptides normalized cortisol circadian rhythms alongside melatonin restoration, demonstrating effects on the hypothalamic-pituitary-adrenal axis [10][11].

Metabolic Modulation

Pineal peptide administration improved glucose tolerance in aged monkeys, reducing the glucose area under the curve from 479.6 to 388.9 mM/min [4]. This metabolic effect is consistent with the known role of melatonin and circadian rhythms in regulating insulin sensitivity and glucose metabolism.

Antioxidant Properties

Endoluten peptides possess antioxidant properties, regulating lipid peroxidation processes in various tissues [1]. This activity is both direct (through peptide-mediated free radical scavenging) and indirect (through restoration of melatonin, which is itself a potent endogenous antioxidant).

Alzheimer's Disease-Relevant Pathways

The EDR peptide (Pinealon) component of Endoluten has been shown to regulate gene expression and protein synthesis in pathways involved in Alzheimer's disease pathogenesis [5][13]. Given that circadian rhythm disruption, melatonin deficiency, and sleep-wake cycle disturbances are common early features of Alzheimer's disease, the pineal peptide's ability to normalize these processes has theoretical relevance to dementia prevention.

3. Researched Applications

Longevity and Mortality Reduction

Evidence level: Limited human clinical data (single research group)

The most significant clinical evidence for pineal peptides comes from Khavinson's long-term mortality studies, conducted with the parent preparation epithalamin rather than the oral form Endoluten:

6-8-year mortality study (266 subjects): Elderly subjects (over 60 years) treated annually with epithalamin experienced a 1.6-1.8-fold reduction in mortality versus controls. When combined with thymalin (thymic peptides), mortality was reduced 4.1-fold over 6 years of annual treatment [2].

15-year follow-up study (70 subjects): A placebo-controlled trial treated elderly adults (~65 years) with "accelerated aging" due to cardiovascular disease with epithalamin (5 intramuscular injections of 10 mg with 3-day intervals) every 6 months for 3 years, then followed them for 12 additional years. Over the full 15-year period, the treatment group showed a 28% decreased all-cause mortality rate, 2-fold lower cardiovascular-specific mortality, prevention of age-associated decline in physical endurance, normalized melatonin production rhythms, and normalized carbohydrate and lipid metabolism [3].

These results are striking but carry the critical caveat that they originate exclusively from Khavinson's research group with no independent replication.

Neuroendocrine Dysfunction and Climacteric Syndrome

Evidence level: Open-label clinical study

Clinical studies of Endoluten were conducted in 163 patients across multiple conditions including dishormonal myocardiodystrophy, physiogenic asthenia, mild and moderate climacteric syndrome in women, and oncological patients after radiation and chemotherapy courses. Endoluten demonstrated restoration of neuroendocrine function and improvement in adaptation to extreme conditions across all groups.

Circadian Rhythm Disorders and Sleep

Evidence level: Preclinical/limited clinical

Based on the demonstrated ability of pineal peptides to restore melatonin production and normalize clock gene expression [7][8], Endoluten is used for age-related sleep disturbances and circadian rhythm disruption. The mechanism is well-supported by molecular data, though specific clinical trials for insomnia or circadian rhythm disorders have not been published.

Age-Related Cognitive Decline

Evidence level: Preclinical/mechanistic

The EDR peptide's effects on Alzheimer's disease-relevant pathways [5][13], combined with the established role of melatonin and circadian rhythms in cognitive health, provide a theoretical basis for using Endoluten in age-related cognitive decline. However, no controlled clinical trials have evaluated cognitive outcomes specifically with Endoluten.

Post-Cancer Treatment Recovery

Evidence level: Included in clinical study cohort

Oncological patients after radiation and chemotherapy courses were included in the 163-patient Endoluten clinical study, with reported improvements in neuroendocrine recovery and adaptation capacity. The pineal gland's sensitivity to radiation damage provides a rationale for this application.

4. Clinical Evidence Summary

5. Dosing in Research

Standard Protocol

The manufacturer recommends 1-2 capsules, 1-2 times daily with meals for 30 days, with courses repeated every 3-6 months. Evening administration is sometimes suggested to align with natural melatonin rhythms, though this timing has not been validated in controlled studies.

Relationship to Epithalamin Dosing

The clinical mortality reduction data was obtained with injectable epithalamin (10 mg per injection, 5 injections per course, courses every 6 months) [3]. The oral Endoluten formulation has different bioavailability characteristics, and the equivalence of oral capsule dosing to injectable epithalamin dosing has not been established through comparative studies.

Combination Protocol

In Khavinson's longevity program, Endoluten is paired with Vladonix (thymic peptides) as the two most critical bioregulators for lifespan extension. The 4.1-fold mortality reduction observed with combined epithalamin plus thymalin significantly exceeded the effect of either preparation alone [2].

6. Safety and Side Effects

Published Safety Data

No adverse effects, toxic reactions, or allergic responses were reported across the clinical studies of Endoluten (163 patients) or the long-term epithalamin trials (up to 15 years of follow-up in 70 subjects) [2][3]. This extended safety record is notable for a peptide preparation, though the total number of monitored subjects remains small.

Safety in Animal Studies

In animal models (mice, Drosophila, rhesus macaques), lifetime or long-term administration of pineal peptides showed no adverse effects on body weight, food consumption, organ function, or behavior [4][10][11][15].

Theoretical Safety Profile

Like all Khavinson peptide bioregulators, Endoluten is proposed to be inherently safe because its peptide components are identical to sequences naturally present in the body. The self-limiting nature of peptide bioregulation -- normalizing but not overstimulating biological processes -- is cited as a fundamental safety mechanism [9][17].

Critical Safety Gaps

Despite the favorable safety record, significant gaps exist:

• No formal toxicology studies meeting international standards
• No pharmacokinetic data for the oral formulation -- absorption, bioavailability, and metabolism undefined
• No drug interaction studies -- interactions with exogenous melatonin supplements, sedatives, immunosuppressants, or hormone therapies are unknown
• Telomerase activation concerns -- the AEDG component activates telomerase, and sustained telomerase activation is associated with oncogenic potential, although animal studies paradoxically showed anti-tumor effects [15]. The finding that AEDG activates the ALT pathway in cancer cells warrants consideration [16]
• No independent safety monitoring outside Khavinson's institution
• As a biological extract, concerns about prion contamination, immunogenicity, and batch variability apply

Contraindications

Manufacturer-listed contraindications include individual intolerance, pregnancy, and breastfeeding.

7. Endoluten Within the Khavinson Bioregulator System

Endoluten is positioned as a cornerstone of Khavinson's comprehensive anti-aging protocol. Within the bioregulator theory, the pineal gland is considered a master regulatory organ whose decline drives systemic aging through loss of melatonin production, circadian disruption, and neuroendocrine dysregulation [1][9].

The Pineal-Thymic Axis

Khavinson's research emphasizes the synergy between pineal peptides (Endoluten/epithalamin) and thymic peptides (Vladonix/thymalin). The theoretical framework proposes that aging results from the coordinate decline of two master regulatory systems:

1. The pineal gland (neuroendocrine regulation, circadian rhythms)
2. The thymus (immune regulation, immunosenescence)

Combined treatment addressing both systems produced the most dramatic mortality reductions in clinical studies [2].

Hierarchy of Bioregulators

In Khavinson's system, Endoluten is classified as a "first-tier" bioregulator alongside Vladonix. Other organ-specific bioregulators (brain, liver, vasculature, adrenal, etc.) are considered secondary to these two master regulatory preparations.

8. Pharmacokinetics

No pharmacokinetic studies have been published for the oral Endoluten formulation. Pharmacokinetic understanding is limited to indirect inferences from the injectable parent preparation epithalamin and from the synthetic peptide Epithalon (AEDG).

Endoluten is administered orally as capsules containing peptides up to 5,000 Da. Oral bioavailability of peptides in this size range is typically very low due to gastrointestinal degradation. The smaller peptide fractions (di- and tripeptides, including EDR/Pinealon) may be absorbed via PepT1 transporters, while larger fractions likely require degradation before absorption. No studies have compared plasma peptide profiles after oral Endoluten versus injectable epithalamin.

The clinical mortality reduction data was obtained with injectable epithalamin (intramuscular, 10 mg per injection) [3], which provides substantially higher systemic bioavailability than oral capsules. The assumption that oral Endoluten reproduces the clinical effects of injectable epithalamin has not been validated through bioequivalence or comparative effectiveness studies. This is a critical gap, as the most significant clinical evidence (28% mortality reduction, melatonin rhythm restoration) applies to the injectable form [3].

For the synthetic component AEDG (Epithalon), no formal PK data exist either, though it has been administered subcutaneously in primate studies with demonstrated biological effects on melatonin production [10][11]. The tetrapeptide's small size (MW ~390 Da) and hydrophilic character suggest rapid renal clearance if it reaches systemic circulation intact.

9. Dose-Response

No dose-response studies have been conducted for oral Endoluten. The clinical study of 163 patients used a fixed protocol (1-2 capsules daily for 30 days) without dose comparison arms.

For injectable epithalamin, the protocol of 10 mg per injection, 5 injections per course (every 3 days), repeated every 6 months, was used in the 15-year follow-up study [3]. Whether more or less frequent courses, higher or lower injection doses, or different course durations would produce different outcomes is unknown. The 6-month inter-course interval was presumably chosen to align with practical clinical scheduling rather than optimized through dose-response analysis.

In primate studies, pineal peptides restored melatonin production in aged monkeys [4][10][11], but the dose-response relationship between peptide dose and melatonin amplitude was not systematically characterized. The glucose tolerance improvement (AUC reduction from 479.6 to 388.9 mM/min) [4] was observed at a single dose level without comparison to higher or lower doses.

10. Comparative Effectiveness

Endoluten vs. Epithalon (AEDG)

Endoluten is the crude pineal extract; Epithalon is the single defined synthetic tetrapeptide derived from it. Epithalon has more precise mechanistic data (telomerase activation, hTERT upregulation, histone binding) and has been independently replicated for telomere elongation [16]. Endoluten may contain additional bioactive peptide fractions beyond AEDG, potentially providing broader effects. The choice between them involves a trade-off between molecular precision (Epithalon) and multi-component coverage (Endoluten).

Endoluten vs. Exogenous Melatonin

Exogenous melatonin (widely available as an OTC supplement) provides direct hormone replacement, while Endoluten proposes to restore endogenous melatonin synthesis capacity. Melatonin supplements have extensive RCT evidence for sleep-onset latency reduction and circadian rhythm adjustment. Endoluten's theoretical advantage is restoration of physiological pulsatile melatonin secretion rather than pharmacological hormone replacement, but this advantage has not been demonstrated in comparative studies.

Endoluten vs. Other Anti-Aging Interventions

The 28% mortality reduction reported with epithalamin over 15 years [3] would, if confirmed by independent replication, place pineal peptides among the most effective anti-aging interventions ever documented. For comparison: caloric restriction extends median lifespan by 10-30% in animal models, rapamycin by 10-15% in mice, and metformin's effects in humans remain under investigation in the TAME trial. However, the epithalamin data comes from a single small study (70 subjects) from one research group, making comparison with independently validated interventions premature.

11. Enhanced Safety

Endoluten has a favorable safety record spanning the 163-patient clinical study and the 15-year epithalamin follow-up in 70 elderly subjects [2][3]. No adverse effects, including no reports of excessive daytime sleepiness, hormonal imbalance, or immunological abnormalities, have been documented. Animal studies in mice, Drosophila, and rhesus macaques similarly reported no adverse effects from lifetime or long-term pineal peptide administration [4][10][11][15].

The telomerase activation by the AEDG component deserves specific safety discussion. While telomerase activation extends cellular lifespan, it is also a hallmark of cancer cells. Paradoxically, animal studies showed that Epithalon reduced spontaneous tumor incidence in mice [15]. The 2025 independent study confirmed that AEDG activates the ALT (alternative lengthening of telomeres) pathway in cancer cells [16], which warrants consideration in individuals with active malignancies. The net oncological effect -- anti-tumor in animal models but with a theoretically pro-proliferative mechanism -- remains unresolved.

As a bovine-derived biological extract, Endoluten carries theoretical risks of prion contamination, immunogenicity, and batch variability not shared by synthetic peptides. No drug interaction studies exist -- interactions with exogenous melatonin, sedative-hypnotics, immunosuppressants, or hormone therapies are unknown. The combined administration with Vladonix (thymic peptides) in longevity protocols introduces additional interaction variables that have not been systematically evaluated.

12. Related Peptides

See also: Epithalon, Thymalin, Cerluten, Cortexin

13. References

1. [1] Khavinson VKh. (2002). Peptides and Ageing. Neuro Endocrinology Letters. PubMed
2. [2] Khavinson VKh, Morozov VG. (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinology Letters. PubMed
3. [3] Khavinson VKh, Kuznik BI, Ryzhak GA. (2012). Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bulletin of Experimental Biology and Medicine. DOI PubMed
4. [4] Goncharova ND, Vengerin AA, Khavinson VKh, Lapin BA. (2005). Pineal peptides restore the age-related disturbances in hormonal functions of the pineal gland and the pancreas. Experimental Gerontology. DOI PubMed
5. [5] Khavinson VKh, Linkova NS, Dyatlova AS, Kantemirova RK, Kozlov KL. (2021). EDR Peptide: possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of Alzheimer's disease. Molecules. DOI PubMed
6. [6] Khavinson VKh, Bondarev IE, Butyugov AA. (2003). Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. DOI PubMed
7. [7] Khavinson VKh, Linkova NS, Kvetnoy IM, Kvetnaia TV, Polyakova VO, Korf HW. (2012). Molecular cellular mechanisms of peptide regulation of melatonin synthesis in pinealocyte culture. Bulletin of Experimental Biology and Medicine. DOI PubMed
8. [8] Ilina A, Khavinson V, Linkova N, Petukhov M. (2025). Overview of Epitalon -- Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. DOI PubMed
9. [9] Khavinson VKh, Anisimov VN. (2000). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
10. [10] Goncharova ND, Khavinson VKh, Vengerin AA, Lapin BA. (2001). Regulatory effect of epithalon on production of melatonin and cortisol in old monkeys. Bulletin of Experimental Biology and Medicine. DOI PubMed
11. [11] Khavinson VKh, Goncharova ND, Lapin BA. (2001). Synthetic tetrapeptide epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuro Endocrinology Letters. PubMed
12. [12] Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. (2004). Peptide promotes overcoming of the division limit in human somatic cells. Bulletin of Experimental Biology and Medicine. DOI PubMed
13. [13] Khavinson VKh, Linkova NS, Dyatlova AS, Kantemirova RK, Kozlov KL. (2022). Neuroepigenetic mechanisms of action of ultrashort peptides in Alzheimer's disease. International Journal of Molecular Sciences. DOI
14. [14] Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). DOI PubMed
15. [15] Anisimov VN, Khavinson VKh, Popovich IG, Zabezhinski MA, Alimova IN, Rosenfeld SV, Zavarzina NY, Semenchenko AV, Yashin AI. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. DOI PubMed
16. [16] Siddiqui S, Garg P, Engelen L. (2025). Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. DOI PubMed
17. [17] Khavinson VKh. (2013). Peptide bioregulators: the new class of geroprotectors. Advances in Gerontology. DOI PubMed